Business, energy, technology, markets and global industry news from Business News Today

anaphylaxis

PharmaDeviceNews anaphylaxis
Needle-free anaphylaxis treatment moves closer to market as Hikma Pharmaceuticals’ epinephrine nasal spray enters regulatory review in the United States, Europe and the United Kingdom, intensifying competition in emergency allergy care. Representative image.
Pharma & Biotech

Hikma advances specialty nasal spray pipeline with global anaphylaxis filings

Hikma’s epinephrine nasal spray enters regulatory review in the U.S., Europe and UK as competition grows in needle-free anaphylaxis treatment.

Read More
Pharma & Biotech

Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway

Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.

Read More
Pharma & Biotech

What Aquestive Therapeutics’ Anaphylm CRL reveals about human factors scrutiny in emergency-use drug approvals

FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.

Read More